The FAERS Public Dashboard and its Value to the Pharmaceutical Industry
Jul 31, 2018 - 00:24:45
Radio and PodcastLive Radio & PodcastsHealth
FDA Confirms Leg and Foot Amputation Risk with Diabetes Medicine Canagliflozin
Based on new data from two large clinical trials, the FDA concluded that the type 2 diabetes medicine canagliflozin (brand names Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. Th...
Related Episodes
Continue listening to more episodes from FDA Drug Information Updates.
FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)
May 4, 2018 - 00:02:59
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
Jan 7, 2018 - 00:08:29
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
Jan 5, 2018 - 00:02:59
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard
Oct 29, 2017 - 00:09:22
FDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease
Aug 17, 2017 - 00:05:29
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
Jul 28, 2017 - 00:06:00